Pharmacokinetic Interaction and the Safety of Inhaled CHF5259 and CHF6001

NCT03004495 | Completed Phase 1

• 1 other identifier: CCD-06302AA1-02
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

To evaluate systemic pharmacokinetics of CHF6001 following concomitant administration of CHF6001 and CHF5259, in comparison with the single components, administered in healthy subjects via a multi-dose reservoir NEXThaler® DPI.

Conditions

Copd

Outcome Measures

Primary Outcomes (2)

• Plasma CHF 5259 and CHF 6001 AUC 0-12,ss (area under the plasma concentration-time curve from time 0 to 12h post dose at steady on Day 14)

  To evaluate the pharmacokinetic interaction between CHF 5259 and CHF 6001

  On Day 1 and Day 14 at pre-dose, within 15 minutes from dosing and at the following time points, 5, 10, 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 12 h post morning dose. At Day 8, Day 12 and Day 13 at pre-dose

• Plasma CHF 5259 and CHF 6001 Cmax,ss (maximum plasma concentration at steady state on Day 14)

  To evaluate the pharmacokinetic interaction between CHF 5259 and CHF 6001

  On Day 1 and Day 14 at pre-dose, within 15 minutes from dosing and at the following time points, 5, 10, 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 12 h post morning dose. At Day 8, Day 12 and Day 13 at pre-dose

Secondary Outcomes (6)

• Plasma CHF 5259 and CHF 6001 and its metabolites (CHF 5956, CHF 6095) AUC0-12h, Cmax, tmax

  On Day 1, Day 14 at the following time points: pre-dose, 5, 10, 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 12 h post-morning dose.

• Holter extracted ECG parameters

  On Day 1, Day 14 at the following time points: pre-dose, 5, 10, 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 12 h post-morning dose.

• Lung function

  On Day 1, Day 14: at pre-dose, 5, 15, 30, 45 min and 1, 2 hours post-morning dose

• Vital signs

  On Day 1, Day 8 and on Day 14 at the following time points: pre-dose, 15 min, 30 min, 1, 2, 4, 8, 12 h post morning dose. From Day 2 to Day 13 at pre-morning dose only, On Day 15 (24 h after last dose), Day 16 (48 h after last dose) and at follow-up. (BP

• Plasma CHF 5259 and CHF 6001 and its metabolites (CHF 5956, CHF 6095) Cmax

  On Day 1, Day 14 at the following time points: pre-dose, 5, 10, 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 12 h post-morning dose.

Study Arms (3)

CHF5259 and CHF6001

EXPERIMENTAL

(T): CHF6001 + CHF5259 b.i.d. for 14 days

Drug: CHF5259 and CHF6001

CHF5259 + placebo

ACTIVE COMPARATOR

(R1): CHF5259 25µg b.i.d. for 14 days

Drug: CHF5259 + placebo; Other: Placebo

CHF6001 + placebo

ACTIVE COMPARATOR

(R2): CHF6001 b.i.d. for 14 days

Drug: CHF6001 + placebo; Other: Placebo

Interventions

CHF5259 and CHF6001 DRUG

b.i.d. for 14 days

Also known as: Test Treatment

CHF5259 and CHF6001

CHF5259 + placebo DRUG

b.i.d. for 14 days

Also known as: Reference Treatment 1

CHF5259 + placebo

CHF6001 + placebo DRUG

b.i.d. for 14 days

Also known as: Reference Treatment 2

CHF6001 + placebo

Placebo OTHER

b.i.d. for 14 days

Also known as: Matching number of inhalations

CHF5259 + placebo; CHF6001 + placebo

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Subject's written informed consent obtained prior to any study-related procedure; Healthy males and females volunteers aged 18-55 years inclusive;
• Ability to understand the study procedures and the involved risks, ability to be trained to use the device correctly
• Non smokers or ex-smokers are eligible.
• Good physical and mental status, determined on the basis of the medical history and a general clinical examination;
• Vital signs checked at screening visit and Day -1: Subjects aged 18-45years: Diastolic BP 40-90, Systolic BP 90-140; Subjects aged 46-55 years: Diastolic BP 40-90, Systolic BP 90-150
• lead digitised Electrocardiogram (12-lead ECG) considered as normal (40≤Heart rate≤110bpm,120 ms ≤ PR ≤ 210 ms, QRS ≤ 120 ms, QTcF ≤ 450 ms for males and ≤ 470ms for females) checked at screening;
• Lung function measurements within normal limits: FEV1 \> 80% of predicted normal value (according to the Global Lung Function Initiative, ERS Task Force Lung Function Reference Values (1,2) ) and FEV1/FVC ratio \> 0.70;
• Male subjects: they and/or their partner of childbearing potential must be willing to use a double contraceptive methods;
• Female subject of non-childbearing potential (WONCBP) Female subjects of childbearing potential (WOCBP) fulfilling one of the following criteria: WOCBP with fertile male partners: they and/or their partner of childbearing potential must be willing to use a double contraceptive methods including one highly effective birth control method and one acceptable birth control method, from the signature of the informed consent and until three months following the last study drug intake; WOCBP with non-fertile male partners: contraception is not required in this case.

You may not qualify if:

• Pregnant or lactating women:
• Blood donation (equal or more than 450 ml) or blood loss less than 12 weeks before inhalation of the study medication;
• Positive HIV1 or HIV2 serology; Positive results from the Hepatitis serology which indicates acute or chronic Hepatitis B or Hepatitis C (positive HB surface antigen (HBsAg),HB core antibody ( anti HBc), HC antibody);
• History of substance abuse or drug abuse within 12 months prior to screening visit;
• Clinically significant abnormal 24-h Holter ECG at screening as defined in the Holter interpretative guidelines (Appendix V);
• Any clinically relevant abnormal laboratory value at screening suggesting an unknown disease and requiring further clinical investigation or which may impact the safety of the subject or the evaluation of the result of the study according to the Investigator's judgment;
• Clinically significant and uncontrolled respiratory, cardiac, hepatic, renal, gastrointestinal, endocrine, metabolic, neurologic, respiratory or psychiatric disorder that may interfere with successful completion of this protocol;
• Subjects with medical diagnosis asthma including childhood asthma;
• Subjects known to have intolerance/ hypersensitivity to M3 Antagonists, or any of the excipients contained in any of the formulations used in the trial;
• Any drug treatment, including prescribed or OTC medicines as well as vitamins, homeopathic remedies etc, taken in the 14 days (3 months for any biologic drugs, enzyme-inducing or enzyme-inhibiting drugs e.g., glucocorticoids, phenobarbital, isoniazid) before the screening visit, with the exception of occasional paracetamol (maximum 2 g per day with a maximum of 10 g per 14 days for mild non-excluding conditions), hormonal contraceptives and hormonal replacement treatment for post-menopausal women;
• Treatment within the previous 3 months before the screening visit with any drug known to have a well defined potential for hepatotoxicity (e.g. isoniazide, nimesulide, ketoconazole);

Sponsors & Collaborators

• Chiesi Farmaceutici S.p.A.: lead
• Quintiles, Inc.: collaborator

Study Sites (1)

Quintiles CPU

London, UK, SE1 1 YR, United Kingdom

Location

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

tanimilast

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Ronnie Beboso, MD

  Quintiles, Inc.

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 28, 2016
• First Posted: December 29, 2016
• Study Start: January 1, 2016
• Primary Completion: August 1, 2016
• Study Completion: August 1, 2016
• Last Updated: December 29, 2016

Record last verified: 2016-12

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)